This week in therapeutics




Licensing status

Publication and contact information


Breast cancer

Plasminogen activator urokinase receptor (PLAUR; uPAR; suPAR)

Mouse studies suggest anti-uPAR antibodies could help treat aggressive breast cancer. In a mouse xenograft model for triple-negative breast cancer, two different anti-uPAR human antibodies inhibited tumor growth. In the same mouse model, a radiotherapeutic-conjugated variant of one of the antibodies caused tumor regression. Next steps include generating sufficient quantities of GMP material for a clinical trial.

SciBX 6(9); doi:10.1038/scibx.2013.211
Published online March 7, 2013

Patent applications filed covering uPAR-binding agents and their methods of use; available for licensing from the University of California, San Francisco Office of Technology Management

LeBeau, A.M. et al. Cancer Res.;
published online Feb. 11, 2013;
Contact: Charles S. Craik, University of California, San Francisco, Calif.